ACADIA Pharma initiates Ph3 CLARITY Program with Pimavanserin for MDD - BSA bureau

Submitted by Anonymous (not verified) on Thu, 04/25/2019 - 12:56

ACADIA Pharma initiates Ph3 CLARITY Program with Pimavanserin for MDD  BSA bureauAccording to the National Institute of Mental Health, MDD affects approximately 16 million adults in the U.S. with approximately 2.5 million adults treated with ...